COMMUNIQUÉ DE PRESSE publié le 26/02/2024 à 14:00, il y a 2 années 7 mois FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM) FSD Pharma Inc. announced an agreement for a clinical trial to test unbuzzd™ effects on faster alcohol metabolism. The trial aims to confirm the supplement's potential benefits in sobering up from alcohol intoxication FSD Pharma Inc. Biopharmaceutical Clinical Trial Unbuzzd™ Alcohol Metabolism
BRÈVE publiée le 26/02/2024 à 14:00, il y a 2 années 7 mois FSD Pharma launches a clinical trial to test the effectiveness of unbuzzd™ FSD Pharma Clinical Test Unbuzzd™ Alcohol Metabolism Accelerated Sobriety
BRÈVE publiée le 26/02/2024 à 14:00, il y a 2 années 7 mois FSD Pharma lance un essai clinique pour tester l'efficacité d'unbuzzd™ FSD Pharma Essai Clinique Unbuzzd™ Métabolisme De L'alcool Sobriété Accélérée
COMMUNIQUÉ DE PRESSE publié le 17/02/2024 à 01:10, il y a 2 années 7 mois FSD Pharma Announces US ATM Offering FSD Pharma announces an at-the-market offering agreement with H.C. Wainwright & Co., LLC to sell Class B Shares for up to US$11,154,232. The Company may use proceeds for clinical trials & general corporate purposes FSD Pharma Biopharmaceutical At-the-market Offering H.C. Wainwright & Co. Class B Shares
COMMUNIQUÉ DE PRESSE publié le 06/02/2024 à 13:00, il y a 2 années 7 mois Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million FSD Pharma Inc. announced that the Court of Appeal for Ontario affirmed the Judgment entered by the Superior Court of Justice. The company also filed a Petition to Confirm Arbitration Awards in the United States District Court for the Eastern District of Pennsylvania FSD Pharma Inc. Court Of Appeal Biopharmaceutical Arbitration Awards Neurodegenerative Disorders
COMMUNIQUÉ DE PRESSE publié le 29/01/2024 à 22:30, il y a 2 années 8 mois FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates FSD Pharma appoints Dr. Sanjiv Chopra to its board of directors, replaces Nitin Kaushal. Also, the company retains SBS Intl Group LLC, Draper Inc., Carriage House Capital, Corp., IR Agency, Beyond Media, Issuer Direct for various services. FSD focuses on biopharmaceutical assets FSD Pharma Dr. Sanjiv Chopra Biopharmaceutical SBS Intl Group LLC IR Agency
COMMUNIQUÉ DE PRESSE publié le 16/01/2024 à 13:30, il y a 2 années 8 mois Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot FSD Pharma Inc., a biopharmaceutical company, provides an update on its litigation with GBB Drink Lab, Inc., denying allegations and moving for discovery. The company remains confident in its legal position and looks forward to vindicating its rights and exposing GBB and its bully tactics. Biopharmaceutical Company FSD Pharma Inc. Litigation Update GBB Drink Lab Inc. Alcohol Detoxification
COMMUNIQUÉ DE PRESSE publié le 23/12/2023 à 01:45, il y a 2 années 9 mois FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC
COMMUNIQUÉ DE PRESSE publié le 05/12/2023 à 15:00, il y a 2 années 10 mois FSD Pharma Inc. Announces Closing of Private Placement FSD Pharma Inc. announces the closing of private placement and issuance of class A multiple voting shares at $1.90 per share for gross proceeds of $45.60. The proceeds will be used for general working capital purposes Private Placement FSD Pharma Inc. Financial News Investment Class A Multiple Voting Shares
COMMUNIQUÉ DE PRESSE publié le 30/11/2023 à 14:30, il y a 2 années 10 mois FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement FSD Pharma Inc. and Celly Nutrition Corp. announce completion of Plan of Arrangement including distribution of Celly Nu Shares and New FSD Pharma Securities to FSD Pharma securityholders FSD Pharma Inc. Plan Of Arrangement Celly Nutrition Corp. Celly Nu Shares New FSD Pharma Securities
Publié le 05/10/2026 à 22:12, il y a 9 heures 29 minutes AXA - Elimination of the dilutive impact of Shareplan 2026
Publié le 05/10/2026 à 22:12, il y a 9 heures 29 minutes AXA - Elimination de l'effet dilutif de l'opération Shareplan 2026
Publié le 05/10/2026 à 18:13, il y a 13 heures 28 minutes Disclosure of shares outstanding and voting rights - 05.10.2026
Publié le 05/10/2026 à 18:13, il y a 13 heures 28 minutes Déclaration nombre d'actions et droits de vote - 05.10.2026
Publié le 05/10/2026 à 18:00, il y a 13 heures 41 minutes LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 septembre 2026
Publié le 05/10/2026 à 22:30, il y a 9 heures 11 minutes EV Nickel Announces Formation of Wholly Owned Subsidiary to Advance Nickel Bioleaching Technology and Canadian Nickel Supply Chain
Publié le 05/10/2026 à 14:45, il y a 16 heures 56 minutes NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Publié le 05/10/2026 à 14:30, il y a 17 heures 11 minutes Hillcrest and Equipmake Expand Partnership Talks to Include Commercial Licensing of ZVS Technology
Publié le 05/10/2026 à 14:30, il y a 17 heures 11 minutes Solitario CEO to Present at John Tumazos Very Independent Research, LLC
Publié le 05/10/2026 à 14:00, il y a 17 heures 41 minutes Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth
Publié le 06/10/2026 à 07:30, il y a 11 minutes REINET INVESTMENTS S.C.A. SHARE BUYBACK PROGRAMME – UPDATE 06 October 2026
Publié le 06/10/2026 à 07:30, il y a 11 minutes Nordex Group secures 228 MW across South, Central and Eastern Europe
Publié le 06/10/2026 à 07:00, il y a 41 minutes Julius Baer Board of Directors announces two new Director nominations